News & Media
Latest Press
Subscribe & Watch
Featured In
In the Press
December 13, 2021
Todos Medical (OTCMKTS: TOMDF) Heats Up as Tollovir 3CL Protease Inhibitor Moves Forward and Antibody, PCR testing & cPass Gain Traction
Todos Medical (OTCMKTS: TOMDF) has been on the move northbound in recent weeks on a steady surge of volume easily topping $1 million in dollar volume per day and emerging as a top traded stock in small caps. With recent highs of $0.1047 the stock needs to break north of this price point for confirmation of the next leg up.
December 7, 2021
Todos Medical says its CLIA/CAP lab Provista Diagnostics enters two new coronavirus PCR testing reference lab contracts
Provista Diagnostics is Todos Medical’s CLIA/CAP certified lab that offers COVID-19 testing solutions that help referring labs keep their clients by allowing them to deliver fast turnaround time at scale
November 30, 2021
Todos Medical Confirms SARS-CoV-2 PCR Test Kits Used at CLIA/CAP Lab Provista Diagnostics Detect Omicron Variant
Todos sees a large market opportunity to gain market share based on the number of inquiries that are focused on Provista Diagnostics’ ability to screen for all variants including Omicron. The lab has reached another milestone as it has reached its COVID-19 PCR testing capacity of 20,000 tests daily. The company also has the capacity to do over 1,500 cPass tests per day, over 5,000 COVID variant tests per day, and over 5,000 respiratory panel tests per day when at full capacity.
November 29, 2021
Todos Medical to acquire all 3CL protease biology-related assets and intellectual property from NLC Pharma
“We began the journey of building 3CL protease biology-based products with Dr. Arad in the second quarter of 2020, just as the pandemic was gaining a foothold globally, and we saw firsthand the power of the technology with initial clinical work on our proprietary diagnostic TolloTest technology,” said Gerald E. Commissiong, President & CEO.
November 29, 2021
“Buzz on the Street” Show: Todos Medical (OTCQB: TOMDF) Agreement with NLC Pharma
FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma.”
November 16, 2021
Todos Medical’s Provista Laboratory to Boost Top Line Through New Atlanta-based Reference Lab Agreement for COVID PCR, cPass Neutralizing Antibody & Respiratory Pathogen Panel Tests
“Business development at Provista is in a pronounced upswing. We see it in the increased throughput and the increasing sales pipeline,” said Gerald E. Commissiong, President & CEO for Todos Medical & Provista.
November 16, 2021
Todos Medical strikes new reference lab deal for Provista Diagnostics; ends 3Q with $1.01M in revenue
Todos said it is anticipating a significant revenue boost from its Provista Diagnostics CLIA/CAP lab business unit beginning in the fourth quarter of 2021 and progressively throughout 2022 as it focuses on driving revenue growth in COVID-19 related diagnostics.
November 16, 2021
Update: Todos Medical Reports Third Quarter 2021 Business and Financial Results
November 5, 2021
A Deep Dive Into COVID Oral Treatments — What Does the Atea Failure Mean for Oral Antivirals?
Are the Remaining Contenders Adamis Pharmaceuticals and Todos Medical?
November 2, 2021
How the COVID-19 Vaccine for Children Differs From Adults’
The next step in the fight against the COVID-19 virus has been the approval of the vaccine for children. Most recently, Pfizer announced that the vaccine that was approved for children is 90 percent effective against COVID-19. Now that the children’s vaccine is here, what was its development like compared to the one for adults? Was it easier or harder? We sat down with Gerald Commissiong, CEO of Todos Medical, to get insight into how the industry has approached the task of vaccine research and testing for different demographics.
October 28, 2021
Pfizer Conceding Race in Hospitalized Covid Because of Todos Medical's Triple MOA Antiviral
The inability of PFE to quickly complete this 5-patient study is the equivalent of a no show at the start of a race. Competitor Todos Medical Ltd. (OTCMKTS: TOMDF) seems to be the only runner left in the hospitalized setting capable of reaching a lucrative endpoint.
October 27, 2021
The world is fighting for COVID treatments, here’s how Israel is helping
“While we are pushing forward with our efforts to complete ongoing clinical studies in Israel and initiate pivotal studies in India, we are also very focused on engaging the US FDA to evaluate Tollovir potentially as part of the emergency use authorization pathway,” Todos Medical President and CEO Gerald Commissiong said.
October 25, 2021
Todos Medical notes publication of article in journal by researchers in Germany which has positive implications for its Tollovir drug
Todos Medical, together with its joint venture partner NLC Pharma, is developing Tollovir, an Mpro (3CL protease) inhibitor currently in a Phase 2 clinical trial for treatment of hospitalized coronavirus (COVID-19) patients with interim data expected from the trial in the fourth quarter of 2021.
October 25, 2021
CFOs Plump Salaries, Perks to Land Elusive New Employees
Finance chiefs are boosting salaries and recruitment spending, offering more in the way of perks and expanding their equity plans as they joust to attract—and retain—workers.
October 25, 2021
Todos Medical says journal article highlights utility of combining cPass and PCR testing to reduce COVID-19 transmission
Todos Medical Ltd has announced the publication of an article entitled “A Practical Approach to SARS-CoV-2 Testing in Pre and Post Vaccination Era” in the peer-reviewed Journal of Clinical Virology, which highlights the clinical utility of combining the cPass neutralizing antibody test in the vaccinated and coronavirus (COVID)-recovered populations with polymerase chain reaction (PCR) testing in the unvaccinated and not previously infected to reduce COVID-19 transmission.
October 21, 2021
Todos Medical Announces Publication in Journal of Clinical Virology Highlighting Clinical Utility of cPass Semi-Quantitative Neutralizing Antibody Test in SARS-CoV-2 Risk Assessment Post-Vaccination or Recovery from Infection
October 19, 2021
Washington State Coach Fired for Refusing Vaccine
CEO Gerald Commissiong comments on the firing of the coach of the Washington State Cougars football team. The head coach and several others were pink-slipped for refusing to get vaccinated against COVID-19.
October 8, 2021
Todos Medical gears up to expand its coronavirus testing services and clinical study
The company is also advancing the commercialization of Tollovid and Tollovid Daily, its oral antiviral 3CL protease inhibiting dietary supplements now available on Amazon.com.
October 6, 2021
Medical Testing Is Entering a New Era, Todos Medical CEO Says
Gerald Commissiong describes how the company's new Covid-19 antibody test works and says the future of early cancer diagnosis could lie in blood testing.
October 6, 2021
Todos Medical CEO Gerald Commissiong comments on: Ellume Recalls About 427,000 COVID-19 Tests
There’s been a recall for hundreds of thousands of COVID-19 test kits. If you used an Ellume home kit recently, there’s a chance your positive test results were false.
October 6, 2021
Todos Medical unveils positive clinical validation data for its 3CL protease biomarker assay TolloTest in a clinical study of COVID-19 patients
The study evaluated TolloTest's sensitivity compared with PCR tests in hospitalized COVID-19 patients, patients hospitalized for conditions other than COVID-19 and individuals exposed to confirmed COVID-19 subjects in the community outpatient setting and healthy control.
October 4, 2021
Todos Medical updates on its COVID-19 antiviral 3CL protease inhibitor Tollovir clinical development program in Israel
It has begun a thorough re-evaluation of outpatient trial designs to provide the fastest path to bring Tollovir to market in outpatient settings based on a lower enrollment threshold required to demonstrate efficacy.
September 30, 2021
Todos notes positive observational trial results for its oral antiviral 3CL protease inhibitor, Tollovir
The company said the treatment group participants, consisting of hospitalized coronavirus patients experienced a reduction in a key inflammatory biomarker.
September 27, 2021
Todos Medical receives Amazon’s approval to sell immune supplements Tollovid and Tollovid Daily
Todos expects to target upcoming family gatherings like Thanksgiving and Christmas where close contact makes it increasingly more important to inhibit 3CL protease to help support the immune system.
September 19, 2021
Todos Medical is now accepting cryptocurrency
Tollovid and Tollovid Daily, Todos Medical Ltd’s exclusive 3CL protease inhibitor health products, are now accepting Bitcoin, Ethereum, Dogecoin, Bitcoin Cash, and Litecoin as payment.
September 15, 2021
Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
September 13, 2021
Todos Medical to Present at H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (Virtual Conference)
September 13, 2021
These OTCQX & OTCQB Securities Had the Most Trading Activity in August
September 7, 2021
Pfizer's 3CL Protease Inhibitor May Cut The Achilles' Heel Of COVID-19
The other 3CL protease inhibitor competitor is a longshot nano-cap company called Todos Medical. Todos is similar to AB Science as it has a promising pipeline of products including its 3CL protease. Other cutting-edge developments include; automated labs for new diagnostic tools for breast cancer and Alzheimer's, as well as a diagnostic platform technology. Its 3CL protease inhibitor is called Tollovir. It is an antiviral, but it is also designed to support immune function. They also have a dietary supplement made of the same active ingredient that supports immune function.
September 3, 2021
Todos Medical completes validation of COVID-19 and respiratory panel tests
Todos Medical Ltd. (OTCQB:TOMDF) CEO Gerald Commissiong tells Proactive its CLIA/CAP certified lab Provista Diagnostics has successfully completed the validation studies required to put the Quidel (NASDAQ:QDEL) (NASDAQ:QDEL) Lyra Influenza A & B and the Lyra RSV & hMPV PCR kits into production.
Commissiong says kits will be produced alongside COVID PCR tests currently being run (Provista Respiratory Panel) and expects this new respiratory panel to be launched in September 2021.
September 2, 2021
Todos Medical launches test that measures COVID-19 antibody levels
Gerald Commissiong, CEO of Todos Medical, joins Yahoo Finance to discuss the latest in antibody test innovation.
September 1, 2021
Todos Medical says its Provista lab completes validation of combo COVID-19, Influenza A & B, and RSV & hMPV respiratory panel test
Todos Medical Ltd. has announced that its CLIA/CAP certified lab Provista Diagnostics has successfully completed the validation studies required to put the Quidel (NASDAQ:QDEL) Lyra Influenza A & B and the Lyra RSV & hMPV PCR kits into production.
The company said kits will be produced alongside COVID PCR tests currently being run (Provista Respiratory Panel) and expects this new respiratory panel to be launched in September 2021.
The validation coincides with the recent validations for the cPass semi-quantitative COVID neutralizing antibody test and the Kogene COVID variant detection kits also being launched in September 2021.
August 27, 2021
Breaking News: Todos Medical’s CLIA/CAP Lab Provista Completes Validation of High-Capacity SARS-CoV-2 Variant Testing Service Capable of Identifying Known Variants
Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP certified lab Provista Diagnostics has successfully completed the validation studies required to put the Kogene Biotech PCR Variant Test Kit (‘Kogene Variant Kit’) into production and expects to launch variant testing in September 2021. The Kogene Variant Kit is a PCR kit capable of identifying the key mutations associated with specific SARS-CoV-2 variants, including the key P681R mutation identified in the Delta variant, that allows Todos to categorize the lineage of the strain responsible for a positive test result. The test can be completed in as little as one hour, significantly faster than genome sequencing, and is highly scalable with the Tecan® liquid handling automation currently onsite at Provista.
August 25, 2021
Todos Medical to Launch New Antibody Blood Test for COVID-19
Todos Medical has completed validation of its cPass neutralizing antibody blood test to monitor COVID-19 immunity.
Todos Medical, a medical diagnostics company, announced that its lab, Provista Diagnostics, has successfully completed the validation studies required to put its cPass neutralizing antibody blood test into production. The company expects to launch the new test in September 2021, and Provista Diagnostics can do up to 20,000 polymerase chain reaction tests and over 1500 cPass tests per day, according to a company press release.
The blood test received Emergency Use Authorization from FDA for the detection of neutralizing antibodies (NAbs) that could be used to monitor key biomarkers of COVID-19. Individuals who acquired their immunity through either vaccination or natural infection will be able to monitor their immunity levels with the device.
August 24, 2021
Todos Medical’s CLIA/CAP Lab Provista Enters Into Reference Lab Agreement with Meadowlands Diagnostics to Provide cPass Neutralizing Antibody Blood Testing for Quantifying and Monitoring Key COVID-19 Immunity Biomarkers
Agreement will enable Meadowlands Diagnostics to offer cPass testing for COVID-19 immunity monitoring to its growing customer base including two additional New Jersey School system contracts
New York, NY, and Tel Aviv, ISRAEL, Aug. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP certified lab Provista Diagnostics has entered into a reference lab agreement to provide cPass neutralizing antibody blood testing services to Meadowlands Diagnostics, a CLIA-certified New Jersey-based provider of laboratory testing services.
Click to Read More
August 24, 2021
Todos Medical Ltd (TOMDF) Stock More Than Doubled: But Why?
Medical diagnostics and associated solutions firm Todos Medical Ltd (OTCMKTS:TOMDF) started the week off with a bang as its stock went up by more than 100% on Monday and in light of such gains, it might be worthwhile to take a look at the announcement that set the rally off.
Yesterday, it was announced by the company that its Chief Executive Officer Gerald Commissiong was going to make an appearance on the show named Varney & Co on the Fox Business Networks yesterday. Considering the fact that Varney & Co is a popular show, the reaction to the news in the markets was understandable and on top of that, the main subject of the discussion may have been a factor as well.
August 24, 2021
Top Covid Stocks In Play After Pfizer Vaccine Approval: TOMDF ENZC TSOI
With the FDA approval of the Pfizer-BioNTech vaccination many biotech stocks moved higher. Leading the microcaps was Todos Medical (OTCMKTS: TOMDF). Shares of leading vaccines makers Pfizer (NYSE: PFE), BioNTech (NASDAQ: BNTX), and Moderna (NASDAQ: MRNA) moved higher on the news due to anticipation of future approvals. The White House immediately took advantage of this approval to pitch the vaccine after hours in a press conference with President Biden claiming that COVID-19 was now a pandemic of the unvaccinated.
August 23, 2021
Todos Medical CEO to Appear on Fox Business Network Varney & Company Today at 11:40am to Discuss the Company’s Launch of cPass Neutralizing Antibody Testing for Monitoring COVID-19 Immunity
New York, NY, and Tel Aviv, ISRAEL, Aug. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Gerald Commissiong, CEO of Todos Medical, is scheduled to appear on Varney & Co. on the Fox Business Network at 11:40 AM Eastern Time today. Mr. Commissiong will discuss the planned launch of cPass neutralizing antibody testing at the Company’s Provista Diagnostics laboratory and how it is expected to empower healthcare professionals and patients with a new tool to monitor their immunity to COVID-19 as booster shots are being rolled out in the United States.
August 23, 2021
Proactive news headlines including Endeavour Mining, PayPal, Alternus Energy, Phunware, Todos Medical and Orgenesis
August 17, 2021
Todos to Present at Upcoming Emerging Growth Conference
August 9, 2021
The Surge in New Cases Reinforces the Importance of a Healthy Lifestyle
Todos Medical Ltd. (OTCQB: TOMDF) announced last week that, "it has received a notice of allowance from the US Patent & Trademark Office (USPTO) for a trademark for the Company's proprietary supplement Tollovid™. The Company received a Certificate of Free Sale (CFS) for the 5-day high dose regimen of Tollovid from the US Food & Drug Administration (US FDA) in April 2021.
August 6, 2021
“Buzz on the Street” Show: Todos Medical (OTCQB: TOMDF) Notice of Allowance for Tollovid
FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Dietary Supplement Tollovid™.”
August 5, 2021
Todos Medical Receipt Notice of Allowance from USPTO for 3CL Protease Inhibitor Dietary Supplement Tollovid™
This USPTO notice of allowance underscores the desire in the marketplace for Tollovid, especially given its high dose, 5-day formulation that helps to support and maintain healthy immune function. Tollovid is a potent botanical, delayed release, bioavailable 3CL protease inhibitor. The Company’s lower dose, delayed release, daily-use formulation Tollovid Daily™ received a CFS from the US FDA in July 2021, including the critical 3CL protease inhibitor claim. Tollovid has high 3CL protease inhibitor activity than Tollovid Daily.
August 1, 2021
50 Smartest Companies of the Year 2021:
Todos Medical is Helping Create a Healthier Future With its Ace Cancer Screening Technology
July 28, 2021
Todos Medical Retains CRO for COVID-19 Outpatient and Inpatient Phase 2/3 Clinical Trials for Oral Antiviral 3CL Protease Inhibitor Tollovir
July 19, 2021
Todos Medical, Fosun Pharma Ink Distribution Agreement for SARS-CoV-2 Neutralizing Antibody Test
July 15, 2021
Todos Medical updates on Phase 2 trial progress to treat hospitalized coronavirus patients in Israel
Todos Medical Ltd (OTCQB:TOMDF) CEO Gerald Commissiong updated Proactive on progress of enrollment of its Phase 2 clinical trial to treat hospitalized coronavirus patients in Israel, with its TolloTest biomarker being used for the first time as a surrogate biomarker to monitor patient response to treatment. Commissiong says recruitment is 'picking up again' due to an increase in coronavirus caseload in Israel.
July 1, 2021
Breaking News: Todos Medical Provides End of Second Quarter 2021 Corporate Update
“The first half of 2021 has seen a dramatic shift in the COVID-19 marketplace in the United States,” said Gerald E. Commissiong, President & CEO of Todos Medical. “In light of the emerging Delta variant circulating widely in the US, there is now a clear need for novel COVID-19 antiviral therapies to protect the unvaccinated and those for whom authorized vaccines do not confer immunity, which includes a large portion of the elderly and those taking immune suppressants, against COVID-19 infection..."
June 19, 2021
Todos Medical (TOMDF) with a $22 Million Market Cap Taking on Pharma Giant Pfizer for COVID-19 Antiviral
TOMDF could beat PFE to the punchline, and if they do, its a multibillion dollar lottery ticket for TOMDF shareholders with only 3 names in the drawing if you you think Merck (MRK) has a chance with molnupiravir.
Investors are bound to reap the rewards from the company that quickly finds the best solution. PFE or TOMDF’s 3CL protease inhibitor is a viable solution to be COVID-19’s Tamiflu, or the Tamiflu for coronaviruses in general. The real question is whether or not they can get it approved in time before the variants decrease the effectiveness of the vaccines.
June 17, 2021
U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs
- Several companies are developing antivirals for COVID-19.
- Pfizer (NYSE:PFE) has PF-07321332 in phase 1, Atea Pharmaceuticals (NASDAQ:AVIR) has AT-527, Merck (NYSE:MRK) and Ridgeback Therapeutics have molnupiravir in phase 3, and Todos Medical's (OTCQB:TOMDF) NLC-V-01 (tollovir).
June 10, 2021
"The question we've got to ask ourselves is: is this something we can stop or is it inevitable?" said Todos Medical CEO Gerald Commissiong..."
Click to Read More
June 3, 2021
Entrepreneurs Are Betting Big on NYC Covid-19 Testing Businesses
Some are getting creative launching or expanding companies, which they believe will be profitable for a long time“It’s likely that it will become endemic because people carry it without knowing or showing symptoms, and some people have diminished immunity that will continue to make them susceptible even post-vaccination,” said Gerald Commissiong..."
Click to Read More
June 2, 2021
"We do not see significant cause for concern because avian flu viruses are significantly less virulent than coronaviruses and have a more difficult time spreading from person to person."
Click to Read More
May 17, 2021
Hopes of Covid breakthrough as Australian scientists develop antiviral injection to kill 99.9% of the virus in the lungs of mice – but it won't be ready for humans until 2023
"Tollovir is being trialled on people by the company Todos Medical in Israel. Todos Medical said past research had shown the drug could work against coronaviruses in general and that it had potential to 'significantly reduce' the severity of Covid."
Click to Read More
April 26, 2021
Pfizer's anti-Covid pill may be ready this YEAR as first human trials are set to end in May – as expert studying another antiviral says effective drugs could end lockdowns forever
Covid-specific therapies being developed include molnupiravir, by Merck and Ridgeback Biotherapeutics; Tollovir, by Todos Medical; and NT-300 by Romark.
April 20, 2021
A PILL to kill third wave: Boris Johnson launches 'ambitious' new 'antivirals taskforce' so Britons can take tablets for Covid at home 'by autumn'
Another, called Tollovir, is being trialled on people by the company Todos Medical in Israel. Todos Medical said past research had shown the drug could work against coronaviruses in general and that it had potential to 'significantly reduce' the severity of Covid.
March 16, 2021
Entrepreneurs Are Betting Big on NYC Covid-19 Testing Businesses
Some are getting creative launching or expanding companies, which they believe will be profitable for a long time
"Manhattan-based Todos Medical mainly develops cancer-detection tests. But next month it will launch what it believes to be the city’s first mobile Covid-testing labs."
Click to Read More
